SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lilly to Present Obesity Drug Data at ObesityWeek 2026

Lilly says it will present data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026. The body begins to reference Phase 2 results for EloraTZP but is truncated.

LLY

Related stories